A new year means a new Fierce Biotech Fundraising Tracker to record all the venture capital being funneled into the industry for 2024. The tracker will focus on fundraising rounds of over $50 million. Some key fundraising rounds highlighted in this edition include:
- BioAge Labs: The biotech company raised $170 million in a Series D financing round. The funds will be used for a phase 2 trial testing BioAge’s lead asset in combination with another drug in patients with obesity.
- ProfoundBio: The biotech company raised $112 million in a Series B round. They are focused on developing antibody-drug conjugates (ADCs) for the treatment of cancer.
- Areteia Therapeutics: The biotech company raised $75 million in an extension of its Series A funding. The funds will be used to continue the development of their oral small molecule drug for eosinophilic asthma.
- Neurona Therapeutics: The biotech company raised $120 million in a Series E round. They are developing a cell therapy for epilepsy.
- Basking Biosciences: The biotech company closed a $55 million fundraise. They are developing a first-in-class RNA aptamer targeting a protein in the blood.
Other companies that raised significant funds include COUR Pharmaceuticals, Eyconis, Synnovation Therapeutics, Calluna Pharma, Accent Therapeutics, Comanche Biopharma, Ratio Therapeutics, Tr1x, Lykos Therapeutics, Claris Bio, Moonwalk Biosciences, Human Immunology Biosciences, and Radionetics Oncology.
